The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

• Status: Recruiting
• Trial end date: 2023-01-03
• Target enrollment: 0
• Participant gender: All

Summary

Esophageal cancer is a kind of disease with high incidence and mortality. Definitive concurrent chemoradiotherapy is an important treatment for locally advanced esophageal squamous cell carcinoma. To Investigate the value of immunotherapy consolidation in locally advanced esophageal squamous cell carcinoma after completing radical concurrent chemoradiotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan University

Criteria

Inclusion Criteria:

• ECOG 0-1; Life expectancy >6 months;

• Stage II/III esophageal cancer;

• Pathology confirmed squamous cell carcinoma;

• Hemoglobin ≥10g/dl, WBC ≥3.0 x 109/L, platelet ≥100 x 109/L; CR≤ 1.0x normal upper limit, total bilirubin ≤ 1.5x normal upper limit, AST and ALT≤ 1.5x normal upper limit, AKP≤ 2.5x normal upper limit;

• Have a full understanding of this study, participate voluntarily, have follow-up conditions and sign the informed consent;

Exclusion Criteria:

• Stage IV esophageal cancer;

• Esophageal adenocarcinoma;

• Gastric esophageal junction adenocarcinoma;

• ECOG > 2;

• Progression after first-course radiotherapy;

• Existing active infection, such as active tuberculosis, hepatitis, etc.;